Status:
NO_LONGER_AVAILABLE
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
10-30 years
Brief Summary
The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildena...
Eligibility Criteria
Inclusion
- Patients Who Completed study A1481156 and Are Judged by the Investigator to Derive Clinical Benefit from Continued Treatment with Sildenafil, Prior to Reimbursement and Availability for Subjects in Russian Federation.
- Child bearing age women should have appropriate contraception.
- Signed informed consent. Patients who have a wish and possibility to follow treatment regimens in terms of the study.
Exclusion
- Pregnant and lactating women.
- Participation in other studies in the current moment or during study period except of A1481156.
- Patients with severe acute or chronic diseases psychiatric disorders or laboratory abnormalities.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01897740
Last Update
December 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moscow Research Institute of Pediatrics and Pediatric Surgery
Moscow, Russia, 125412